bluebird bio Announces First Patient Transplanted In Phase 1/2 HGB-205 Study For The Treatment Of Beta-Thalassemia And Sickle Cell Anemia

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq:BLUE) a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced that the first subject with beta-thalassemia major has been enrolled in its phase 1/2 HGB-205 study in France and has undergone infusion with bluebird bio’s LentiGlobin drug product in an autologous hematopoietic stem cell transplantation.

Help employers find you! Check out all the jobs and post your resume.